Opens in a new tab

Genevant Sciences v Moderna (CFI, 23 May 2025)

Date23 May 2025
CourtCFI
DivisionThe Hague (NL) Local Division
Type of actionPreliminary objection
Registry referenceApp_19773/2025 · ORD_21852/2025
PartiesModerna Italy S.R.L., Moderna France SASU, Moderna Germany GmbH, Moderna Poland SP. Z.O.O., Moderna Netherlands B.V., Moderna Denmark ApS, …

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By joint order of 23 May 2025 in the joined infringement actions UPC_CFI_191/2025 (EP 2 279 254) and UPC_CFI_192/2025 (EP 4 241 767) brought by Genevant Sciences and Arbutus Biopharma against fifteen Moderna group companies, the judge rapporteur of The Hague Local Division largely dismissed the preliminary objections. Those of Moderna Belgium and Moderna Germany, and of Moderna Poland in case 192, were late, the long-arm jurisdiction issue was left to the main proceedings.

Question

Were the objections raised within one month, does the UPC have jurisdiction over the Spanish, Polish and Norwegian companies, is The Hague division competent, and was the opt-out of EP 2 279 254 validly made and withdrawn?

Decision

The Rule 19.1 period runs from service: objections lodged on 24 April 2025 were late for the companies served first, which are deemed to accept jurisdiction (Rule 19.7) (paragraphs 11 to 13). The UPC, as a common court, applies Arts 7(2) and 8(1) of Regulation No 1215/2012 through Art. 71b: alleged joint infringement with Moderna Netherlands is enough, whether infringement actually occurred being a matter for the merits (paragraphs 15 to 18). Membership of the same group with related activities establishes the « commercial relationship » under Art. 33(1)(b) (paragraph 19). Arbutus, successor to Protiva by merger on 1 January 2018, was entitled to make and withdraw the opt-out. The Rule 8.5(c) presumption was rebutted (paragraphs 18 and 19, case 191).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 31, 32(1)(a), 33(1)(a) and (b) and 63
Rules of Procedure
Rules 8.5(c), 19.1 and 19.7
Regulation (EU) No 1215/2012
Arts 7(2), 8(1), 71a and 71b
Other instruments
revised Lugano Convention, Arts 5(3) and 7(1)
Case law cited
Court of Appeal, 3 September 2024 (UPC_CoA_188/2024), Munich Local Division, 29 September 2023 (UPC_CFI_15/2023), Paris Local Division, 11 April 2024 (UPC_CFI_495/2023)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Local and central divisions (UPC).

Dhenne Avocats blog: The Transitional Period and the UPC: Coordinating Two Judicial Orders.

Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, Valeo v. Bosch and the Redistribution of Cases Within the UPC (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Preliminary objection
Outcome (Dhenne Avocats summary)
Les exceptions préliminaires de Moderna sont rejetées, sauf irrecevabilité pour tardiveté de certaines d'entre elles. La compétence internationale et locale est retenue, l'opt-out est jugé valablement formé et retiré, et la question long-arm est renvoyée au fond.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 279 254
Novel lipid formulations for nucleic acid delivery
recorded proprietor: Arbutus Biopharma Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 7 other decision(s): Genevant Sciences v Moderna (CFI, UPC_CFI_191/2025, 25 August 2026) · Genevant Sciences v Moderna (CFI, 18 August 2025) · Genevant Sciences v Moderna (CFI, 13 August 2025) · Genevant Sciences v Moderna (CFI, 4 August 2025) · Genevant Sciences v Moderna (CFI, 12 June 2025) · Moderna v Genevant Sciences (CFI, 4 June 2025) · Genevant Sciences v Moderna (CFI, 17 April 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
EP 4 241 767Mentioned in the analysis (role not qualified)
Also mentioned in 5 other decision(s): Genevant Sciences v Moderna (CFI, UPC_CFI_192/2025, 25 August 2026) · Genevant Sciences v Moderna (CFI, 18 August 2025) · Genevant Sciences v Moderna (CFI, 12 June 2025) · Moderna v Genevant Sciences (CFI, 4 June 2025) · Genevant Sciences v Moderna (CFI, 17 April 2025)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.